Supplementary Table. Gene expression profiling reveals a decrease in NFkB-driven gene signature pattern upon treatment with MLN4924. Gene ID Name Treated/ untreated fold ratio P value BCL2L1 (Bcl-xL) BCL2-like 1, nuclear gene encoding mitochondrial protein, transcript variant 1 0.51 0.0008 BCL2 B-cell CLL/lymphoma 2, nuclear gene encoding mitochondrial protein, transcript variant alpha 0.66 0.02 BCL2L11 (Bim) BCL2-like 11 (apoptosis facilitator) (BCL2L11), transcript variant 6 1.96 0.000005 CCND1 Homo sapiens cyclin D1 0.29 GADD45B Growth arrest and DNA-damage-inducible, beta 0.34 0.00006 CCND2 Homo sapiens cyclin D2 0.45 0.0003 STAT5A Signal transducer and activator of transcription 5A 0.58 0.00009 CCL22 Chemokine ligand 22 0.06 0.0000009 CXCL9 Chemokine (C-X-C motif) ligand 9 0.27 0.004 CD40 CD40 molecule, TNF receptor superfamily member 5, transcript variant 2 0.41 0.00003 CD74 CD74 molecule, major histocompatibility complex, class II invariant chain, transcript variant 1 0.42 CXCR7 Chemokine (C-X-C motif) receptor 7 0.43 0.002 CCL5 Chemokine ligand 5 CCL17 Chemokine ligand 17 0.49 CXCR3 Chemokine (C-X-C motif) receptor 3 0.64 0.003 CXCR5 Chemokine (C-X-C motif) receptor 5 0.81 0.04 MIR155HG MIR155 host gene (non-protein coding) 0.11